FLT4 Antibodies

Vascular endothelial growth factor receptor 3 (FLT4)

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, migration and survival of endothelial cells, and regulates angiogenic sprouting.

Signaling by triggered FLT4 leads to improved production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. The secreted isoform 3 may be a decoy receptor for VEGFC and/or VEGFD and play an essential part as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis.

Gene Information

Human
Gene Name:	FLT4
Uniprot:	P35916
Entrez:	2324

Family

Belongs to:
protein kinase superfamily

Alternative Names

EC 2.7.10; EC 2.7.10.1; FLT4; Flt-4; fms-related tyrosine kinase 4; LMPH1A; PCLFLT41; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; Tyrosine-protein kinase receptor FLT4; vascular endothelial growth factor receptor 3; VEGF R3; VEGFR3; VEGFR-3; VEGFR3Fms-like tyrosine kinase 4

Molecular Weight

Mass (kDA):
152.757 kDA

Genomic Context

Human
Location:	5q35.3
Sequence:	5; NC_000005.10 (180601506..180650298, complement)

Tissue Specificity

Detected in endothelial cells (at protein level). Widely expressed. Detected in fetal spleen, lung and brain. Detected in adult liver, muscle, thymus, placenta, lung, testis, ovary, prostate, heart, and kidney.

Subcellular Localizations

Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Ligand-mediated autophosphorylation leads to rapid internalization.; [Isoform 1]: Cell membrane; Single-pass type I membrane protein. Ligand-mediated autophosphorylation leads to rapid internalization.; [Isoform 2]: Cell membrane; Single-pass type I membrane protein.; [Isoform 3]: Secreted. Cytoplasm.

Diseases

• Neoplasms
• Tumor Angiogenesis
• Lymphedema
• Milroy Disease
• Malignant Neoplasms
• Neoplasm Metastasis
• Pathologic Neovascularization
• Edema
• Leukemia
• Malignant Paraganglionic Neoplasm
• Lymphatic Metastasis
• Carcinoma

• Chromosomal Translocation
• Hemangioma
• Chimera Disorder
• Adenocarcinoma
• Fibromyalgia
• Cell Invasion
• Lymphoma

Interacting Proteins

• HSP90AB1
• KDR
• VEGFC

Pathways

• Angiogenesis
• Lymphangiogenesis
• Localization
• Pathogenesis
• Vasculogenesis
• Cell Proliferation
• Cell Growth
• Cell Migration
• Transport
• Endothelial Cell Proliferation
• Wound Healing
• Dna Methylation
• Methylation

• Regulation Of Angiogenesis
• Cell Adhesion
• Immune Response
• Neurogenesis
• Autocrine Signaling
• Chemotaxis
• Translation

PTMs

• Phosphorylation
• Glycosylation

• Cleavage
• Methylation

• Demethylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/FLT4

What Are The Best Uses Of The FLT4 Marker?

What are the Best Uses of The FLT4 Markers These questions are the same ones that scientists are asked every day. This is because the FLT4 marker is able to be used in a variety of scientific research. In addition to the applications, Boster scientists can use the markers to study specific samples, species and other things. Boster is able to make this marker widely accessible because scientists around the globe can submit their findings and receive product credits.

VEGF-C

Like all VEGF family proteins, there are many variations of the FLT4 gene that can affect its biological activity. The present invention aims to find useful analogs for the FLT4 gene. The RIPA lysis buffer was used to extract the protein. The concentration of protein was determined using a bicinchoninic Acid protein assay kit (Pierce). The proteins were separated using polyacrylamide gel electrophoresis. The gel-grown proteins were then transferred to PVDF membranes and blocked with 5% nonfat milk/Tris-buffered saline Tween-20. The membranes were then incubated with the FLT1 primary antibody (Scientific Information, Methods, and Conclusions) for at least one night.

Immunohistochemistry is one of the most popular methods to detect proteins. This technique employs antibody-antigen interactions to identify specific cellular components in a sample. For a successful immunohistochemical analysis, scientists must optimize the procedure of preparing and staining samples. Once the samples are stained and dried, they will produce an extremely strong signal that can be used to interpret. The FLT4 marker is a great tool for researchers whose work requires high-quality antibodies.

Using this marker for discovery of drugs has opened many avenues for research. It not only targets VEGFC but also targets, a hormone that promotes tumorigenesis. Utilizing this gene as a biomarker could provide more effective treatments for cancer. It is also being used in clinical trials due to its numerous therapeutic applications. So how do we identify the most effective drug?

There are many applications for Flow Cytometry and IHC-P analysis. The boster bio anti-VEGFC antibody could be used for imaging purposes. The antibody reacts with the polypeptide VEGF-C coding sequence in cells, allowing researchers to determine if a drug is able to produce a functional FLT4 protein. Boster Bio can supply FLT4 antibodies for your research.

There are many other uses of the FLT4 gene. One of these applications is the creation of a drug that can treat cancer. One of these uses is to treat patients suffering from leukemia or other inflammatory diseases. The treatment of cancerous cells is aimed at targeting the FLT4 gene through inhibiting the production of VEGF. This drug will stop cancer growth by reducing inflammation through its effects.

The FLT4 gene is a protein coding gene that plays a part in a myriad of biological pathways. It regulates the angiogenic sprouting as well as the migration of endothelial cells. It is also linked to the CREB pathway as well as the Apoptotic Pathways in Synovial Fibroblasts. Many biological assays employ FLT4 antibodies. Boster Bio uses monoclonal or polyclonal antibodies that react with the protein of interest.

The invention's polypeptides can trigger VEGFC receptors. They also promote endothelial migration and may be useful in cancer treatment, tissue transplantation, and eye diseases. The invention's polypeptides could activate the VEGF receptor and stimulate or inhibit VEGF C biological functions. They may be useful in the treatment of many illnesses and are able to be utilized in clinical trials.

The VEGF-C protein has been shown to be a key promoter of lymphatic vessel formation. It has critical roles in tumorigenesis, embryogenesis and metastasis. It is a binding agent for VEGF receptors found on lymphatic endothelial cells. For instance, VEGF receptors found in breast cancer cells stimulate VEGF-C. Therefore, the FLT4 gene is useful to study various objectives.

The FLT4 gene plays a part in epilepsy. It also is associated with vascular regeneration and temporal regulation of VEGF expression. Additionally FLT4 can be a valuable marker in neurogenesis. It also influences the expression of other genes or signaling pathways. The potential for epilepsy research is exciting. This gene is at the heart of many epilepsy treatments.

The FLT4 gene can be found in the heart and skeletal muscle. Other cells in the body also carry the gene. VEGF-C and PlGF are an excellent example of a tumor-related growth factors. These hormones may form heterodimers and exert various physiological functions. A RNAi-based analysis is a good way to identify the FLT4 gene in tumor tissue.

VEGF-A impedes neuron growth and migration in the brain and is involved in epileptogenesis. It exerts its functions when VEGF is bound to VEGFR2 within the nervous system. The neurons are weakened during the latent phase, which suggests that FLT4 may play a role in epileptogenesis. It could also aid in reducing the severity of epilepsy in children.

VEGF-A

In this study, we show that the presence as well as the amount of FLT4 marker can be determined by using small interference RNA mediated by lentivirus. Small interfering RNAs mediated by lentivirus reduce lymphangiogenesis and tumor growth. The results are reported in Anat Rec (Hoboken), 292:633-640. This study can be used for a variety of purposes in veterinary research and diagnostics.

One of the best methods for detecting proteins is immunohistochemistry, which uses antibody-antigen interactions to visualize the distribution and localization of particular cellular components. Researchers improve the preparation of samples and staining procedures to produce powerful signals. The result of an effective immunohistochemistry procedure provides a clear representation of the presence or absence of a specific protein, and can be used to confirm a variety of biological processes and diagnose illnesses.

The angiogenesis process is controlled by VEGF receptors. They control the proliferation and migration of endothelial cell populations. Activation of VEGF signals is downstream of the VEGFR2 receptor. Both VEGF-A and VEGFB are crucial regulators of cancer angiogenesis in living. The two proteins share homology in structure, and share 8 cysteines between them.

The FLT4 Marker is an essential gene for research in a variety of fields. The FLT4 gene was discovered by researchers in the year 2008 and its function has been demonstrated in many areas. The FLT4 gene plays an important role in cancer, neuroscience and a variety of other diseases. Its use in cancer research is anticipated to grow exponentially in the coming years, following the discovery of new diseases.

Research has also shown that epileptic discharges can be controlled by lowering VEGF expression in tumors. This could be due epileptogenesis being controlled during the latent phase. It also helps to reduce epileptic seizures in the SRS. It is also essential to know the mechanisms of epilepsy and its treatment.

NSC proliferation is aided by VEGF expression. Additionally, the increase in VEGF expression protects neurons in the CA1 and CA3 regions from an ectopic transfer. Since the FLT4 gene has been shown to be extremely relevant in a wide range of applications and applications, it could be a target for the development of drugs. FLT4-directedRNAi has many benefits.

VEGF-C RNAi decreases tumor cell growth and promotes apoptosis, both in vivo and in vitro. A study of 4T1 breast cancer cells showed that siV2 (one microgram/g body weight) significantly reduced the tumor size. The treatment with siV2 resulted in significantly less tumor weight than the BC group.

Muders MH examined prostate cancer cells. The FLT4 gene regulates the expression of VEGF-C. It blocks VEGF-C expression in 4T1 cells. Other studies have revealed that VEGF-C also blocks gastric cancer cell growth. FLT4 is also used in cancer research to treat many types of cancer. FLT4 can also be utilized to treat tumors for different reasons.

The specificity of the antibody can be increased with the use of anti-FLT4 antibodies. Boster's antibodies are highly cited and validated in Western Blotting, Immunohistochemistry, and ELISA. Additionally, they are highly specific and are able to recognize multiple species. This is why they are useful in a variety of applications. Don't delay in starting research with FLT4 antibodies.

It is crucial to keep in mind that this gene is involved with a variety of epileptogenesis. It is a crucial neurovascular target in the brain diseases that affect the brain's function and development. In particular, VEGF regulates hippocampal neurogenesis and microvascular regeneration, and it is thought that its inhibition can reduce SRS severity. However, further research is needed to determine whether VEGF and FLT4 are effective in neurovascular treatments.